MARC Record from marc_columbia

LEADER: 03315cam a2200361Ii 4500
001 12842526
005 20171016134733.0
008 170223s2017 dcua b 000 0 eng d
019 $a973797437$a973914754
020 $a0309455626
020 $a9780309455626
035 $a(OCoLC)ocn973754834
035 $a(OCoLC)973754834$z(OCoLC)973797437$z(OCoLC)973914754
035 $a(NNC)12842526
040 $aYDX$beng$erda$cYDX$dNRC$dSOI
050 4 $aR723.7$b.D69 2014
100 1 $aDowney, Autumn S.,$erapportuer.
245 10 $aReal-world evidence generation and evaluation of therapeutics :$bproceedings of a workshop /$cAutumn Downy, Amanda Wagner Gee, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Health and Medicine Division, the National Academies of Sciences, Engineering, Medicine.
264 1 $aWashington, DC :$bNational Academies Press,$c2017.
264 4 $c©2017.
300 $axvi, 85 pages :$bcolor illustrations ;$c23 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
504 $aIncludes bibliographical references.
505 0 $aIntroduction -- Improving evidence generation for decision making on approval and use of new treatments: some stakeholder priorities -- Opportunities for real-world data -- Generating and incorporating real-world evidence into medical product development and evaluation: building from successful case studies -- Potential strategies for a way forward -- Appendix A: Bibliography -- Appendix B: Workshop agenda -- Appendix C: Participant biographies -- Appendix D: Discussion paper: real-world evidence to guide the approval and use of new treatments.
520 $a"The volume and complexity of information about individual patients is greatly increasing with use of electronic records and personal devices. Potential effects on medical product development in the context of this wealth of real-world data could be numerous and varied, ranging from the ability to determine both large-scale and patient-specific effects of treatments to the ability to assess how therapeutics affect patients' lives through measurement of lifestyle changes. In October 2016, the National Academies of Sciences, Engineering, and Medicine held a workshop to facilitate dialogue among stakeholders about the opportunities and challenges for incorporating real-world evidence into all stages in the process for the generation and evaluation of therapeutics. Participants explored unmet stakeholder needs and opportunities to generate new kinds of evidence that meet those needs. This publication summarizes the presentations and discussions from the workshop"--Publisher's description.
650 0 $aEvidence-based medicine$xData processing$vCongresses.
700 1 $aGee, Amanda Wagner,$erapporteur.
700 1 $aClaiborne, Anne B.,$erapporteur.
710 2 $aNational Academies of Sciences, Engineering, and Medicine (U.S.).$bForum on Drug Discovery, Development, and Translation,$eissuing body.
776 08 $iOnline version :$aDowney, Autumn S.$tReal-world evidence generation and evaluation of therapeutics.$dWashington, DC : National Academies Press, [2017]$z9780309455633$w(OCoLC)993587827
852 00 $boff,sci$hR723.7$i.D69 2014g